The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Lipocalin 2 is essential for chronic kidney disease progression in mice and humans
Open accessAbstract
Mechanisms of progression of chronic kidney disease (CKD), a major health care burden, are poorly understood. EGFR stimulates CKD progression, but the molecular networks that mediate its biological effects remain unknown. We recently showed that the severity of renal lesions after nephron reduction varied substantially among mouse strains and required activation of EGFR. Here, we utilized two mouse strains that react differently to nephron reduction--FVB/N mice, which develop severe renal lesions, and B6D2F1 mice, which are resistant to early deterioration--coupled with genome-wide expression to elucidate the molecular nature of CKD progression. Our results showed that lipocalin 2 (Lcn2, also known as neutrophil gelatinase-associated lipocalin [NGAL]), the most highly upregulated gene in the FVB/N strain, was not simply a marker of renal lesions, but an active player in disease progression. In fact, the severity of renal lesions was dramatically reduced in Lcn2-/- mice. We discovered that Lcn2 expression increased upon EGFR activation and that Lcn2 mediated its mitogenic effect during renal deterioration. EGFR inhibition prevented Lcn2 upregulation and lesion development in mice expressing a dominant negative EGFR isoform, and hypoxia-inducible factor 1α (Hif-1α) was crucially required for EGFR-induced Lcn2 overexpression. Consistent with this, cell proliferation was dramatically reduced in Lcn2-/- mice. These data are relevant to human CKD, as we found that LCN2 was increased particularly in patients who rapidly progressed to end-stage renal failure. Together our results uncover what we believe to be a novel function for Lcn2 and a critical pathway leading to progressive renal failure and cystogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron
Flo, T. H., Smith, K. D., Sato, S., Rodriguez, D. J., Holmes, M. A., Strong, R. K., Akira, S., & Aderem, A. (2004) · Nature · doi:10.1038/nature03104 · Cited by 1,877
Goetz, D. H., Holmes, M. A., Borregaard, N., Bluhm, M. E., Raymond, K. N., & Strong, R. K. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00708-6 · Cited by 1,355
Chronic kidney disease: the global challenge
El Nahas, A. M., & Bello, A. K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17789-7 · Cited by 1,195
Mori, K., Lee, H. T., Rapoport, D., Drexler, I. R., Foster, K., Yang, J., Schmidt-Ott, K. M., Chen, X., Li, J. Y., Weiss, S., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23056 · Cited by 954
Self-citationDual Action of Neutrophil Gelatinase–Associated Lipocalin
Schmidt-Ott, K. M., Mori, K., Li, J. Y., Kalandadze, A., Cohen, D. J., Devarajan, P., & Barasch, J. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080882 · Cited by 772
Self-citationA Cell-Surface Receptor for Lipocalin 24p3 Selectively Mediates Apoptosis and Iron Uptake
Devireddy, L. R., Gazin, C., Zhu, X., & Green, M. R. (2005) · Cell · doi:10.1016/j.cell.2005.10.027 · Cited by 672
An Iron Delivery Pathway Mediated by a Lipocalin
Yang, J., Goetz, D., Li, J.-Y., Wang, W., Mori, K., Setlik, D., Du, T., Erdjument-Bromage, H., Tempst, P., Strong, R., et al. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00710-4 · Cited by 651
Self-citationMechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes
Remuzzi, G. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27699 · Cited by 618
Genetics and Pathogenesis of Polycystic Kidney Disease
Igarashi, P., & Somlo, S. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000028643.17901.42 · Cited by 593
Fine, L. G., & Norman, J. T. (2008) · Kidney International · doi:10.1038/ki.2008.350 · Cited by 515
Berger, T., Togawa, A., Duncan, G. S., Elia, A. J., You-Ten, A., Wakeham, A., Fong, H. E. H., Cheung, C. C., & Mak, T. W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510847103 · Cited by 460
Self-citationExcerpts from the US Renal Data System 2009 Annual Data Report
Collins, A. J., Foley, R. N., Herzog, C., Chavers, B. M., Gilbertson, D., Ishani, A., Kasiske, B. L., Liu, J., Mau, L.-W., McBean, M., et al. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.10.009 · Cited by 436
Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach
Lautrette, A., Li, S., Alili, R., Sunnarborg, S. W., Burtin, M., Lee, D. C., Friedlander, G., & Terzi, F. (2005) · Nature Medicine · doi:10.1038/nm1275 · Cited by 343
Self-citationKuwabara, T., Mori, K., Mukoyama, M., Kasahara, M., Yokoi, H., Saito, Y., Yoshioka, T., Ogawa, Y., Imamaki, H., Kusakabe, T., et al. (2009) · Kidney International · doi:10.1038/ki.2008.499 · Cited by 302
Self-citationMechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats
Kliem, V., Johnson, R. J., Alpers, C. E., Yoshimura, A., Couser, W. G., Koch, K. M., & Floege, J. (1996) · Kidney International · doi:10.1038/ki.1996.95 · Cited by 281
Holmes, M. A., Paulsene, W., Jide, X., Ratledge, C., & Strong, R. K. (2005) · Structure · doi:10.1016/j.str.2004.10.009 · Cited by 246
Model of robust induction of glomerulosclerosis in mice: Importance of genetic background
Ma, L.-J., & Fogo, A. B. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00058.x · Cited by 246
Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor
Sweeney, W. E., Chen, Y., Nakanishi, K., Frost, P., & Avner, E. D. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00829.x · Cited by 219
Ding, H., He, Y., Li, K., Yang, J., Li, X., Lu, R., & Gao, W. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.01.010 · Cited by 208
Biomarkers in acute and chronic kidney disease
Nickolas, T. L., Barasch, J., & Devarajan, P. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282f4e525 · Cited by 200
Self-citationSmith, L. A., Bukanov, N. O., Husson, H., Russo, R. J., Barry, T. C., Taylor, A. L., Beier, D. R., & Ibraghimov-Beskrovnaya, O. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006020136 · Cited by 200
Richards, W. G., Sweeney, W. E., Yoder, B. K., Wilkinson, J. E., Woychik, R. P., & Avner, E. D. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2071 · Cited by 197
Strutz, F., Zeisberg, M., Hemmerlein, B., Sattler, B., Hummel, K., Becker, V., & Müller, G. A. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00997.x · Cited by 183
Inhibition of Lipocalin 2 Impairs Breast Tumorigenesis and Metastasis
Leng, X., Ding, T., Lin, H., Wang, Y., Hu, L., Hu, J., Feig, B., Zhang, W., Pusztai, L., Symmans, W. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1934 · Cited by 176
Terzi, F., Burtin, M., Hekmati, M., Federici, P., Grimber, G., Briand, P., & Friedlander, G. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8315 · Cited by 175
Self-citationHIF in Kidney Disease and Development
Gunaratnam, L., & Bonventre, J. V. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008070804 · Cited by 173
Lipocalins in drug discovery: From natural ligand-binding proteins to ‘anticalins’
Schlehuber, S., & Skerra, A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03294-5 · Cited by 171
Progression of Renal Disease and Renal Hypertrophy
Hostetter, T. H. (1995) · Annual Review of Physiology · doi:10.1146/annurev.ph.57.030195.001403 · Cited by 166
Neutrophil Gelatinase-associated Lipocalin, a Siderophore-binding Eukaryotic Protein
Borregaard, N., & Cowland, J. B. (2006) · BioMetals · doi:10.1007/s10534-005-3251-7 · Cited by 165
Bolignano, D., Coppolino, G., Campo, S., Aloisi, C., Nicocia, G., Frisina, N., & Buemi, M. (2007) · American Journal of Nephrology · doi:10.1159/000103912 · Cited by 160
Zeng, F., Singh, A. B., & Harris, R. C. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.08.005 · Cited by 150
Lipocalin 2-Dependent Inhibition of Mycobacterial Growth in Alveolar Epithelium
Saiga, H., Nishimura, J., Kuwata, H., Okuyama, M., Matsumoto, S., Sato, S., Matsumoto, M., Akira, S., Yoshikai, Y., Honda, K., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.12.8521 · Cited by 133
Lipocalin 2: A multifaceted modulator of human cancer
Yang, J., & Moses, M. A. (2009) · Cell Cycle · doi:10.4161/cc.8.15.9224 · Cited by 131
Mehrpour, M., Arrabal, S., Jalil, A., Pinson, X., Gaudin, C., Piétu, G., Pitaval, A., Ripoche, H., Éloit, M., Dormont, D., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1735 · Cited by 122
Shepard, H. M., Brdlik, C. M., & Schreiber, H. W. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36049 · Cited by 119
Iron Accumulation in Human Chronic Renal Disease
Nankivell, B. J., Boadle, R. A., & Harris, D. C. H. (1992) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)70222-6 · Cited by 116
Mouse oncogene protein 24p3 is a member of the Lipocalin protein family
Flower, D. R., North, A. C. T., & Attwood, T. K. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)81256-2 · Cited by 114
Hakroush, S., Moeller, M. J., Theilig, F., Kaissling, B., Sijmonsma, T., Jugold, M., Akeson, A. L., Traykova-Brauch, M., Hosser, H., Hähnel, B., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080792 · Cited by 106
Neutrophil gelatinase-associated lipocalin: new paths for an old shuttle.
Devarajan, P. (2007) · PubMed · Cited by 88
Stöcklin, E., Botteri, F. M., & Groner, B. (1993) · The Journal of Cell Biology · doi:10.1083/jcb.122.1.199 · Cited by 88
Proliferation and Remodeling of the Peritubular Microcirculation after Nephron Reduction
Pillebout, É., Burtin, M., Yuan, H. T., Briand, P., Woolf, A. S., Friedlander, G., & Terzi, F. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61726-9 · Cited by 74
Self-citationNature and Severity of the Glomerular Response to Nephron Reduction Is Strain-Dependent in Mice
Esposito, C., He, C., Striker, G. E., Zalups, R. K., & Striker, L. J. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65336-9 · Cited by 73
JunD protects against chronic kidney disease by regulating paracrine mitogens
Pillebout, É., Weitzman, J. B., Burtin, M., Martino, C., Fédérici, P., Yaniv, M., Friedlander, G., & Terzi, F. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17647 · Cited by 67
Self-citationStone, C. E., Hall, D. H., & Sundaram, M. V. (2009) · Developmental Biology · doi:10.1016/j.ydbio.2009.02.030 · Cited by 62
Feng, W., Karihaloo, A. K., Yu, Z., Marlier, A., Seth, P., Shibazaki, S., Wang, T., Somlo, S., Cantley, L. G., & Sukhatme, V. P. (2008) · Kidney International · doi:10.1038/ki.2008.395 · Cited by 56
Urinary NGAL Marks Cystic Disease in HIV-Associated Nephropathy
Paragas, N., Nickolas, T. L., Wyatt, C. M., Forster, C. S., Sise, M. E., Morgello, S., Jagla, B., Buchen, C., Stella, P., Sanna‐Cherchi, S., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009010065 · Cited by 51
Self-citationAn introduction to biomarkers: applications to chronic kidney disease
Lemley, K. V. (2007) · Pediatric Nephrology · doi:10.1007/s00467-007-0455-9 · Cited by 22
Cited by
Villanueva, E., Yalavarthi, S., Berthier, C. C., Hodgin, J. B., Khandpur, R., Lin, A. M., Rubin, C. J., Zhao, W., Olsen, S. H., Klinker, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100450 · Cited by 1,241
Chakraborty, S., Kaur, S., Guha, S., & Batra, S. K. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.03.008 · Cited by 503
Cellular and molecular mechanisms of kidney fibrosis
Djudjaj, S., & Boor, P. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.06.002 · Cited by 475
Biomarkers in chronic kidney disease: a review
Fassett, R. G., Venuthurupalli, S. K., Gobe, G. C., Coombes, J. S., Cooper, M. A., & Hoy, W. E. (2011) · Kidney International · doi:10.1038/ki.2011.198 · Cited by 449
Lipocalin 2: an emerging player in iron homeostasis and inflammation
Xiao, X., Yeoh, B. S., & Vijay-Kumar, M. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064559 · Cited by 426
Metadata
- Authors
- Viau, A., El Karoui, K., Laouari, D., Burtin, M., Nguyen, C., Mori, K., Pillebout, E., Berger, T., Mak, T. W., Knebelmann, B., Friedlander, G., Barasch, J., & Terzi, F.
- Venue
- Journal of Clinical Investigation
- Published
- 2010-11-01
- Volume
- 120
- Issue
- 11
- Pages
- 4065-4076
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2001370885
- Cited by
- 392
- References
- 49
- FWCI
- 14.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.